Chip stocks fall with Nvidia after data center rev disappointment
Investing.com - Leerink Partners has doubled its price target on Brii Biosciences Ltd (HK:2137) to HK$2.00 from HK$1.00 while maintaining a Market Perform rating following the company’s first-half 2025 financial report and clinical program updates.
The research firm highlighted new data from Cohort 4 of the ENSURE study showing that prior treatment with BRII-179 can induce robust anti-Hepatitis B Surface Antigen responses and identify patients more likely to achieve HBsAg loss. The data suggests HBsAg reduction may be achievable with shorter PEG-IFNα treatment duration of 24 weeks.
Brii Biosciences has engaged with China’s Center for Drug Evaluation on potential Phase 3 study design and expects further discussions following 24-week follow-up data from ENSURE Cohort 4, anticipated in the second half of 2025.
The company reported progress across multiple clinical programs, including the initiation of a new triple combination cohort in the ENHANCE study and a strategic out-licensing agreement with Joincare Group for soralimixin.
Financially, Brii reduced its research and development expenses by 7.3% and administrative expenses by 26.0% compared to the first half of 2024, ending the period with a cash position of US$289.9 million, which management indicates is sufficient to support operations through 2028.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.